TACE联合阿帕替尼对晚期肝癌的临床疗效(1)
[摘要] 目的 探讨肝动脉灌注化疗栓塞术(transcatheter arterial chemoembolization，TACE)联合阿帕替尼治疗晚期肝癌的临床疗效与单独TACE治疗晚期肝癌患者的临床疗效的差异。 方法 选择2016年3月～2017年3月我院收治的晚期肝癌患者50例，将其随机分为实验组和对照组，每组25例。其中，实验组进行TACE联合口服阿帕替尼治疗，对照组只进行TACE治疗。30 d为1个疗程，两组患者共同治疗3个疗程。比较两组的治疗效果、生活质量、肝功能及不良反应情况。 结果 实验组的客观缓解率(88%)明显高于对照组(48%)(P<0.05)；躯体功能、心理功能、症状/副作用、社会功能及生活质量总得分均高于對照组(P<0.05)；谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBil)水平均低于对照组(P<0.05)；且发热、恶心、呕吐等不良反应发生率均小于对照组(P<0.05)。 结论 TACE联合口服阿帕替尼对肝癌患者的治疗率有所提高，同时晚期肝癌患者的生活质量和肝功能状况也所有改善，此外副作用也降低。
[关键词] 晚期肝癌；阿帕替尼；TACE；疗效
[中图分类号] R735.7 [文献标识码] B [文章编号] 1673-9701(2018)22-0090-03
[Abstract] Objective To explore the difference between the clinical efficacy of transcatheter arterial chemoembolization(TACE) combined with apatinib and that of TACE alone in patients with advanced hepatocellular carcinoma. Methods A total of 50 patients with advanced hepatocellular carcinoma admitted inour hospital from March 2016 to March 2017 were selected and randomly divided into the experimental group and the control group， with 25 cases in each group. Among them， the experimental group was treated with TACE combined with oral apatinib， and the control group was treated with TACE only. 30 days was a course of treatment. Two groups of patients were treated with 3 courses. The treatment effect，quality of life， liver function and adverse reactions of the two groups were compared. Results The objective remission rate in the experimental group (88%) was significantly higher than that in the control group (48%)(P<0.05)； the total scores of physical function， psychological function， symptoms/side effects， social function and quality of life in the experimental group were all higher than those in the control group(P<0.05). Aspartate aminotransferase(AST)， Alanine aminotransferase(ALT)， total bilirubin (TBil) levels in the experimental group were lower than those of the control group(P<0.05). And the incidence of adverse reactions such as fever，nausea，vomiting was lower than that of the control group(P<0.05). Conclusion The therapeutic rate of TACE combined with oral apatinib in patients with liver cancer has been improved. At the same time，the quality of life and liver function of patients with advanced liver cancer have also been improved， and the side effects have also been reduced.
[Key words] Advanced liver cancer； Apatinib； TACE； Efficacy
晚期肝癌是全球发病率第三高的恶性肿瘤[1]，我国的肝癌患者死亡人数占世界肝癌死亡人数的50%[2]。晚期肝癌有肿瘤细胞扩散和远处转移的现象，已丧失手术切除的机会，TACE是目前晚期肝癌应用最为广泛的治疗手段[3]。肝癌细胞中表皮生长因子受体(Epidermal growth factor receptor，EGFR)和血管内皮细胞生长因子受体(Vascular endothelial growth factor receptor，VEGFR)等信号转导通路都呈高表达，在其发生、发展进程中起重要作用[3]。阿帕替尼是一种新型的口服血管内皮生长因子受体-2的多激酶抑制剂，可抑制肿瘤血管生成，抑制肿瘤生长[4]。, 百拇医药(白松涛 张月蒙)
[关键词] 晚期肝癌；阿帕替尼；TACE；疗效
[中图分类号] R735.7 [文献标识码] B [文章编号] 1673-9701(2018)22-0090-03
[Abstract] Objective To explore the difference between the clinical efficacy of transcatheter arterial chemoembolization(TACE) combined with apatinib and that of TACE alone in patients with advanced hepatocellular carcinoma. Methods A total of 50 patients with advanced hepatocellular carcinoma admitted inour hospital from March 2016 to March 2017 were selected and randomly divided into the experimental group and the control group， with 25 cases in each group. Among them， the experimental group was treated with TACE combined with oral apatinib， and the control group was treated with TACE only. 30 days was a course of treatment. Two groups of patients were treated with 3 courses. The treatment effect，quality of life， liver function and adverse reactions of the two groups were compared. Results The objective remission rate in the experimental group (88%) was significantly higher than that in the control group (48%)(P<0.05)； the total scores of physical function， psychological function， symptoms/side effects， social function and quality of life in the experimental group were all higher than those in the control group(P<0.05). Aspartate aminotransferase(AST)， Alanine aminotransferase(ALT)， total bilirubin (TBil) levels in the experimental group were lower than those of the control group(P<0.05). And the incidence of adverse reactions such as fever，nausea，vomiting was lower than that of the control group(P<0.05). Conclusion The therapeutic rate of TACE combined with oral apatinib in patients with liver cancer has been improved. At the same time，the quality of life and liver function of patients with advanced liver cancer have also been improved， and the side effects have also been reduced.
[Key words] Advanced liver cancer； Apatinib； TACE； Efficacy
晚期肝癌是全球发病率第三高的恶性肿瘤[1]，我国的肝癌患者死亡人数占世界肝癌死亡人数的50%[2]。晚期肝癌有肿瘤细胞扩散和远处转移的现象，已丧失手术切除的机会，TACE是目前晚期肝癌应用最为广泛的治疗手段[3]。肝癌细胞中表皮生长因子受体(Epidermal growth factor receptor，EGFR)和血管内皮细胞生长因子受体(Vascular endothelial growth factor receptor，VEGFR)等信号转导通路都呈高表达，在其发生、发展进程中起重要作用[3]。阿帕替尼是一种新型的口服血管内皮生长因子受体-2的多激酶抑制剂，可抑制肿瘤血管生成，抑制肿瘤生长[4]。, 百拇医药(白松涛 张月蒙)